Aveanna Healthcare Holdings Inc. (AVAH) Stock Price & Analysis
Aveanna Healthcare Holdings Inc. (AVAH) closed at USD 13.32 on Thursday, October 22, 2026, up 2.54% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 12.99; the Oct 22, 2026 session ranged USD 13.03–13.34 on volume of 1,776,912 shares. Market capitalization is $2.91B, with a 52-week range of USD 5.93–14.71 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AVAH.md
Key facts (AVAH)
- 1 of 80 tracked superinvestors hold AVAH (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 2.09 on a 1–5 scale) (11 analysts), mean target USD 14.85 (range 13–16).
- Total return with dividends: 1Y +46.0% vs S&P 500 +14.9%; 5Y +84.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD 0.21, revenue estimate $681M.
Superinvestors (SEC 13F-HR, Q2 2026) (AVAH)
1 of 80 tracked investors hold AVAH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $6.6M | Reduced -0.3% |
Analysts (AVAH)
Consensus Buy (mean 2.09 on a 1–5 scale), 11 analysts; mean target USD 14.85 (low 13, high 16).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-14 | JP Morgan | Target raised | Neutral | $8 → $15 |
| 2026-08-28 | Barclays | Target raised | Overweight | $9.5 → $15 |
| 2026-08-24 | Truist Securities | Target raised | Hold | $11 → $15 |
| 2026-08-24 | RBC Capital | Target raised | Outperform | $10 → $16 |
| 2026-08-14 | UBS | Target raised | Neutral | $8 → $13 |
| 2026-08-14 | Raymond James | Target raised | Strong Buy | $13 → $15 |
| 2026-08-14 | BMO Capital | Target raised | Outperform | $10 → $14 |
| 2026-07-14 | Truist Securities | Target raised | Hold | $9 → $11 |
| 2026-07-09 | Barclays | Target raised | Overweight | $9 → $9.5 |
Total return (dividends reinvested) (AVAH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +46.0% | +84.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +46.2% | +13.0% |
| Volatility (annualized) | 47.6% | 75.5% |
| Max drawdown | -36.9% (Oct 2025→Apr 2026) | -91.3% (Nov 2021→Nov 2022) |
AVAH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.21 | $0.17 | +20.3% | $680.6M | 10 |
| Next quarter (ends Dec 2026) | $0.21 | $0.18 | +17.2% | $694.9M | 10 |
| Current fiscal year (ends Dec 2026) | $0.82 | $0.71 | +16.8% | $2.69B | 11 |
| Next fiscal year (ends Dec 2027) | $0.91 | $0.77 | +17.2% | $2.90B | 11 |
Key Statistics (as of October 23, 2026 at 09:25 UTC)
| Price | USD 13.32 |
|---|---|
| Change | ▲ 2.54% (up) |
| Previous Close | USD 12.99 |
| Open | USD 13.1 |
| Day Range | USD 13.03 – 13.34 |
| 52-Week Range | USD 5.93 – 14.71 |
| Volume | 1,776,912 shares |
| Market Cap | $2.91B |
| Exchange | NMS |
Technical Analysis (AVAH)
Nexqual's technical model rates AVAH "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:25 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.49 (neutral) |
| vs SMA50 | Above (USD 13.03) |
| MACD | 0.01 (positive) |
Analyst Ratings (AVAH)
Wall Street analysts rate AVAH "Buy" based on 11 analysts, with a mean price target of USD 14.85 (range USD 13–16), per Nexqual as of October 23, 2026 at 09:25 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 14.85 |
| High Target | USD 16 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 8 / 3 / 0 |
Earnings (AVAH)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD 0.21 |
| Revenue Estimate | $680.62M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.22 vs est 0.17 ▲ beat |
| 2026-03-31 | USD 0.18 vs est 0.13 ▲ beat |
| 2025-12-31 | USD 0.17 vs est 0.16 ▲ beat |
| 2025-09-30 | USD 0.15 vs est 0.13 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financials & Fundamentals (AVAH)
| Total Revenue | $2.60B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +13.70% |
| Gross Margin | +32.04% |
| Operating Margin | +12.58% |
| Profit Margin | +10.56% |
| ROE | +198.57% |
| Debt / Equity | 5.23 |
| Current Ratio | 1.16 |
| Total Cash | $109.23M |
| Total Debt | $1.51B |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financial Health Score (AVAH)
Nexqual rates Aveanna Healthcare Holdings Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:25 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 32%, operating 13% (last 12 months) |
| Balance Sheet | Critical — $109M cash vs $1.51B debt |
| Cash Flow | Solid — Operating cash flow $126M (FY ended Jan 2026, 10-K) |
| Efficiency | Strong — ROE 199%, ROA 9.7% |
Ownership (AVAH)
| Insider Ownership | +5.64% |
|---|---|
| Institutional Ownership | +94.22% |
| Shares Outstanding | 218.29M |
| Float | 104.42M |
| Short % of Float | +6.32% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Leadership (AVAH)
Aveanna Healthcare Holdings Inc. is led by Jeffrey S. Shaner, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:25 UTC.
| President, CEO & Director | Jeffrey S. Shaner |
|---|---|
| Executive Chairman | Rodney D. Windley |
| CFO & Principal Financial Officer | Matthew Buckhalter |
| Chief Operating Officer | Kristy Rohwedder |
| President of Home Health & Hospice | Shane Brinkerhoff |
Major Backers & Investors (AVAH)
Notable institutional backers of Aveanna Healthcare Holdings Inc. include Bain Capital Investors Llc, J.H. Whitney Equity Partners VII, LLC, Nut Tree Capital Management, LP, according to Nexqual as of October 23, 2026 at 09:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bain Capital Investors Llc | 37.39% |
| J.H. Whitney Equity Partners VII, LLC | 12.4% |
| Nut Tree Capital Management, LP | 5.92% |
| Ophir Asset Management Pty Ltd | 2.34% |
| Braidwell LP | 1.4% |
| Boston Partners | 1.32% |
| Fidelity | 1.1% |
| Citadel | 1.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.4% |
| Vanguard Group | 1.68% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACHC | Acadia Healthcare Company, Inc. | USD 31.88 | ▲ 1.43% |
| GRDN | Guardian Pharmacy Services, Inc | USD 39.59 | ▲ 1.56% |
| BKD | Brookdale Senior Living Inc. | USD 10.19 | ▲ 1.09% |
| MD | Pediatrix Medical Group, Inc. | USD 29.55 | ▲ 5.16% |
| ADUS | Addus HomeCare Corporation | USD 122.67 | ▲ 4% |
| NHC | National HealthCare Corporation | USD 243.07 | ▲ 3.17% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt